ArticleMedicine2025
Trends in the incidence, survival, and prognostic nomogram of angiosarcoma in the United States.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Evolution of retiform hemangioendothelioma into angiosarcoma.JAAD case reports · 2026Article
- Characteristics, Outcomes, and Risk Factors in Primary and Secondary Angiosarcoma: A Retrospective Cohort Study.The breast journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the epidemiological trends of angiosarcoma and to establish a tool to estimate its prognosis. Data from the Surveillance, Epidemiology, and End Results (SEER) database (1975-2016) were used to assess trends in the epidemiology of angiosarcoma, and a nomogram was established based on independent prognostic factors. The age-adjusted incidence of angiosarcoma gradually increased from 0.13/100,000 in 1975 to 0.33/100,000 in 2016 (annual percentage change [2.4]). The most significant increase was observed in patients aged ≥ 60 years. The same increasing trend was observed across all the stages and grades. The limited-duration prevalence increased from 0.0003% in 1992 to 0.0013% in 2016 (P < .05). In multivariable analyses, age, sex, marital status, grade, historical stage, surgery, site, and tumor size were independent prognostic factors for angiosarcoma. The concordance index of the nomogram was significantly higher than that of the American Joint Committee on Cancer (AJCC) 6th edition and the AJCC 7th edition (0.74 vs 0.61 vs 0.66, respectively). Calibration analysis showed optimal agreement between nomogram predictions and actual observations. The incidence and prevalence of angiosarcoma has increased over the past 40 years. We established a nomogram to predict the overall survival of patients with angiosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.